In this study, we also identified DNMBP-rs10786578 genotypes as another potential candidate for predicting the efficacy of post-resection 5-FU-based adjuvant chemotherapy in stage II/III CRC patients. The gene discussed is DNMBP; the disease is colorectal carcinoma.